Atom Bioworks offers AptaBLE
Product
Transformer-based AI platform from Atombio for aptamer discovery and optimization in days.
- Currently Offered
Transformer-based AI platform from Atombio for aptamer discovery and optimization in days.
AptaBLE (Aptamer Binding LanguagE) is Atombio's aptamer discovery and optimization platform. It is a transformer-based AI model trained on proprietary data from protein-aptamer interactions, and it generates pools of aptamer candidates and optimizes existing aptamers for performance.
The platform designs aptamers with nuclease resistance achieved without chemical modifications, using proprietary databases and nucleic acid self-structure insights, and counter-selects candidates against the human proteome to reduce off-target binding. The aptamers serve as targeting ligands with smaller size (5–15 kDa versus 150–170 kDa for antibodies), lower immunogenicity, site-directed conjugation, manufacturability through in vitro chemical synthesis, tunable affinity, and stability across temperature and pH ranges.
Atlas is a licensable protein-interaction data ecosystem from A-Alpha Bio for AI-enabled protein design.
AI platform for de novo antibody and protein design against challenging drug targets.
Compass is Inductive Bio virtual bench platform embedding AI models, lab automation, and chemists in small-molecule discovery.
NucleIQ is Creyon's AI-powered nucleic acid engineering platform for designing oligonucleotide-based medicines.
AI-guided cyclic-oligonucleotide platform for designing ASO, siRNA, and sgRNA drug candidates.
Aptamer delivery platform for tissue-specific delivery of RNA payloads including siRNA, ASO, and LNPs.
HyperBind is an AI antibody design platform that learns from experimental feedback.
Atlas is a licensable protein-interaction data ecosystem from A-Alpha Bio for AI-enabled protein design.
AI platform for de novo antibody and protein design against challenging drug targets.
Compass is Inductive Bio virtual bench platform embedding AI models, lab automation, and chemists in small-molecule discovery.
EvoGen is a generative AI platform that designs novel therapeutic proteins.
NucleIQ is Creyon's AI-powered nucleic acid engineering platform for designing oligonucleotide-based medicines.
Agentic AI platform for RNA drug discovery covering ASO and siRNA design through lead optimization.
AI-guided cyclic-oligonucleotide platform for designing ASO, siRNA, and sgRNA drug candidates.
Aptamer delivery platform for tissue-specific delivery of RNA payloads including siRNA, ASO, and LNPs.